| Patent Application | Protection Through To | Status in Key Territories | Scope |
|---|---|---|---|
|
Access III |
2024 |
Granted – US, Europe, Japan, Korea, China, India, others |
Claims support novel use of the two excipients |
|
Access V |
2029 |
Granted – US, Europe, China and other territories |
Aspect of protease inhibition |
|
Access VI * |
2040 |
International examination revealed no prior art; 2 countries granted. Divisionals |
Stimulation of cell uptake, using 3 excipients |
|
Access VII * |
(2041) |
Now in National phase |
Extension of protease inhibition |
|
Access VIII * |
(2043) |
Recently filed |
Permeation of mucin |
|
Access IX |
(2044) |
Filed March 2024, proceeding with national phase entry in all major territories |
Long-Acting formulations/Lipidated peptides |
|
Access X |
(2046) |
Filed May 2026 |
Microdosing for maintenance and avoidance of rebound |
* Composition of matter
